The Value Signal — September 18, 2026

730 articles scanned · 12 high-signal

Signal Map

Executive Summary

Washington is tightening the economics of VBC: CMS is expanding care-access models while auditors, rating bodies and drug-pricing officials raise the cost of weak documentation, thin quality performance and opaque rebate strategy.

CMMI and Medicare economics are moving from pilots to pressure points: CMS announced an expansion of the ACCESS Model, according to American Hospital Association, while Scan Health and Walmart are teaming on Medicare Advantage plans, Modern Healthcare reports. The signal for VBC operators is clear: distribution, access and model participation are becoming strategic levers, not side programs.

Risk adjustment and pricing scrutiny are intensifying: federal watchdog audits accused Humana and UnitedHealthcare Medicare Advantage plans of upcoding that generated nearly $180 million in overpayments over two years, Healthcare Dive reports, while recent False Claims Act settlements show Medicare Advantage diagnosis-coding programs face a widening enforcement pattern, according to Jdsupra. On the pharmacy side, CMS has exempted drugmakers from two Medicare pricing demonstrations if they provide additional Medicaid rebates, Endpoints reports, underscoring a more transactional federal approach to drug-cost containment.

Quality and coverage administration are also becoming more visible performance tests: NCQA released its 2026 Health Plan Ratings to show plan performance on key measures and member satisfaction, NCQA reports. The Milbank Memorial Fund highlights proposals to federalize state Medicaid payments for Medicare premiums and cost sharing, while AASM says its 2027 Medicare physician fee schedule comments flagged policies affecting sleep medicine; together, these point to a benefits environment where specialty access, dual-eligible financing and public quality signals are increasingly tied to plan credibility.